Mature T cells recognize and respond to the antigen/MHC complex through their antigen-specific receptors (TCR). The most immediate consequence of TCR activation is the initiation of signaling pathways including induction of specific protein tyrosine kinases (PTKs), breakdown of phosphatidylinositol 4,5-biphosphate (PIP2), activation of protein kinase C (PKC) and elevation of intracellular calcium ion concentration. These early events are transmitted to the nucleus and result in
clonal expansion of T cells
upregulation of activation markers on the cell surface
differentiation into effector cells
induction of cytotoxicity or cytokine secretion
induction of apoptosis
One of the most common ways to assess T cell activation is to measure T cell proliferation upon in vitro stimulation of T cells via antigen or agonistic antibodies to TCR.
This protocol is written as a starting point for examining in vitro proliferation of mouse splenic T-cells and human peripheral T cells stimulated via CD3. Critical parameters include cell density, antibody titer and activation kinetics.
1X sterile PBS
Anti-mouse CD3e, Clone 145-2C11 (Functional Grade, Cat. No. 16-0031, or Purified, Cat. No. 14-0031)
Complete RPMI-1640
Sterile single-cell suspension of mouse spleen or lymph nodes
96-well flat-bottom microtiter plates with lids (Costar Cat. No. 3596)
MTT Buffer
MTT Lysing Solution
Concanavalin A, optional (ConA, Sigma Cat. No. C5275)
Pipettes and pipettors, Multichannel pipettor
Centrifuge
37°C, CO2 incubator
96-well micro test spectrophotometer
2 hours to coat antibody to flask or plate
20 minutes preparation of spleen single cell suspension
20 minutes to set up the assay
2-4 days incubation
Antibody Coating of the Assay Plate Microwells:
Prepare a 5-10μg/ml solution of anti-CD3e (145-2C11) in sterile PBS. Calculate the number of wells required for each experimental condition and consider triplicate samples for each condition. For example, to coat one-half plate (48 wells) 2.6ml of antibody solution is required. Note: We have performed titration studies and found these concentrations of 145-2C11 to induce a maximal response. However, a pilot experiment to determine efficacy of other concentrations of this antibody to induce cellular activation can be performed. For costimulation studies using antibodies to other antigens, a suboptimal activation with anti-CD3 may be required. To achieve suboptimal activation via anti-CD3, a 0.5-0.1μg/ml 145-2C11 antibody solution can be used.
Dispense 50μl of the antibody solution to each well of the 96-well assay plate. For the control unstimulated wells, add 50μl of sterile PBS.
Tightly cover the plate with ParafilmTM to avoid sample evaporation and incubate at 37°C for 2 hours or prepare the plate one day in advance and keep at 4°C overnight.
Just before adding cells, remove the 50μl antibody solution with a multichannel pipettor.
Rinse each well with 200μl of sterile PBS and discard PBS.
Repeat step 5 to remove all unbound antibody from each well.
Addition of Cells:
Harvest spleen and prepare a single cell suspension under sterile conditions. Follow the red cell lysis protocol to remove red cells.
Count cells and resuspend in complete RPMI-1640 at 106/ml. Note: This density of spleen cells gives a good response. If experimental conditions require, a titration of cell densities (2-3x106/ml to 105/ml) should be performed for optimization.
After washing the wells with PBS (step 6 above), add 200μl of the cell suspension to each well and place in a humidified 37°C, 5% CO2 incubator. Note: For an additional stimulation control, incubate cells in 3 wells with Concanavalin A at 1-4μg/ml of culture medium.
Incubate for 2-4 days. Note: Proliferation of cells between days 2 and 4 gives a good response; however, this incubation time can also be optimized for specific experimental conditions.
Add 20μl of the MTT buffer to each well and put back in the incubator for 4 hours.
Add 50μl of the MTT Lysis Solution to each well, vortex gently and incubate overnight.
Read the plate at 570nm the next day.
Calculate the mean and standard errors and graph the data.
Human PBMCs can be activated in vitro by soluble anti-human CD3 antibodies. We have performed titration studies with these antibodies and established the following protocol for stimulation of PBMC.
1X sterile PBS
Anti-human CD3:
Complete RPMI-1640
Sterile PBMC
96-well flat-bottom microtiter plates with lids (Costar Cat. No. 3596)
MTT Buffer
MTT Lysing Solution
Pipettes and pipettors, Multichannel pipettor
Centrifuge
37°C, CO2 incubator
96-well micro test spectrophotometer
30 minutes preparation of PBMC
20 minutes to set up the assay
2-4 days incubation
Prepare PBMC and resuspend the cells at 1-2x106/ml of complete RPMI. Note: This density of PBMC gives a good response. If experimental conditions require, a titration of cell densities (2-3x106/ml to 105/ml) should be performed for optimization.
Add 100μl of the cell suspension to each well. For each condition, use triplicate wells.
Add soluble antibody in 100μl to each well. Titrate antibodies for optimal performance in the assay conditions used. If isolated T cells are to be used in proliferation assays, we recommend using these antibodies at 10μg/ml immobilized on plastic (i.e. bound to wells of 96-well assay plates).
Place in a humidified 37°C, 5% CO2 incubator.
Incubate for 2-4 days. Note: Proliferation of cells between day 2 and 4 gives a good response; however, this incubation time can also be optimized for specific experimental conditions.
Add 20μl of the MTT buffer to each well and put back in the incubator for 4 hours.
Add 50μl of the MTT Lysis Solution to each well, vortex gently and incubate overnight.
Read the plate at 570nm the next day.
Calculate the mean and standard errors and graph the data.
Complete RPMI-1640:
900ml RPMI-1640 (Hyclone Cat. No. SH30027.02)
100ml FBS (Hyclone Cat. No. SH30151.03) Heat inactivated (10% final)
1ml 2-mercaptoethanol (Gibco BRL Cat. No. 21985-023)
10ml L-Glutamine (Hyclone Cat. No. SH30034.01)
Antibiotic cocktail (optional)
MTT Buffer:
MTT (Sigma Cat. No. M5655) 5mg/ml stock solution in 1X PBS - Keep protected from light.
MTT Lysing Solution:
20% SDS 50% DMF
為單克隆抗體和抗體偶聯藥物反相分離樹立新標桿美國馬薩諸塞州米爾福德市,2018年2月1日-沃特世公司近日隆重推出BioResolveRPmAb多苯,450?,2.7μm實心核色譜柱,用于完整單克隆抗體......
獲得性免疫反應(adaptiveimmunity)的關鍵特征之一是抗原的特異性。不同的病原微生物能夠引發各自特異的后天免疫反應,然而,其中的分子機制目前了解的并不清楚。獲得性免疫反應的起始是由T細胞表......
CD3單克隆抗體(OKT3) CD3分子是由肽鏈以非共價鍵組成的復合分子,在成熟T細胞表面表達,對阻斷急性同種異體排斥反應起主要作用。CD3分子與TCR組成復合受體分子,激活酪氨酸激酶,促使......